Your SlideShare is downloading. ×
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

2013 US Tumor Marker Testing Market: Opportunities and Strategies for Supplier

81

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
81
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. 2013 US Tumor Marker Testing Market: Opportunities andStrategies for SupplierReport Details:Published:December 2012No. of Pages: 620Price: Single User License – US$8700Highlights•Comprehensive 620-page analysis of the US tumor marker testing market.•Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.•Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.•Ten-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices.•Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.•Current instrumentation technologies and feature comparison of leading analyzers.•Sales and market shares of leading suppliers.•Emerging diagnostic technologies and their potential market applications.•Product development opportunities.•Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.•Business opportunities and strategic recommendations for suppliers.Get your copy of this report @http://www.reportsnreports.com/reports/213057-2013-us-tumor-marker-testing-market-opportunities-and-strategies-for-supplier.htmlMajor points covered in Table of Contents of this report includeTable of ContentsIntroduction
  • 2. Worldwide Market and Technology OverviewA. Cancer Statistics and Etiology1. Brest Cancer2. Lung Cancer3. Colon and Rectum Cancer4. Prostate Cancer5. Stomach Cancer6. Leukemia7. Lymphoma8. Oral Cancer9. Skin Cancer10. Uterine Cancer11. Ovarian Cancer12. Bladder CancerB. Major Current And Emerging Cancer Diagnostic Tests1. Introduction2. Tumor Marker Classification3. ACTH4. Alpha-Fetoprotein (AFP)5. Beta-2 Microglobulin6. CA 15-3/27.297. CA 19-98. CA-1259. Calcitonin10. Carcinoembrionic Antigen (CEA)11. Estrogen and Progesterone Receptors12. Ferritin13. Gastrin14. Human Chorionic Gonadotropin (HCG)15. Insulin16. NSE17. Occult Blood18. PAP Smear/HPV19. Prostatic Acid Phosphatase (PAP)20. Prostate-Specific Antigen (PSA)21. Squamous Cell Carcinoma Antigen (SCC)22. T and B Lymphocytes23. TdT24. Thyroglobulin25. Tissue Polypeptide Antigen (TPA)26. Biochemical Tumor MarkersADA
  • 3. B-ProteinPNP5-Nucleotidase27. OncogenesAbl/abl-bcrAIB1BCL-2BRCA1CD44C-fosC-mybC-mycCYP-17Erb-BHPC1N-mycP40P51P53PIK3CAPTI-1RasRegSisSrc28. Polypeptide Growth Factors? Basic Fibroblast Growth FactorBeta-TGFCachectin (TNT)CalmodulinECFRNerve Growth Factor (NGF)Epidermal Growth Factor (EGF)Ornithine DecarboxylaseTransferrinTransforming Growth Factor-Alpha29. Ectopic Hormones30. Colony Stimulating Factors31. LymphokinesAlpha-InterferonB Cell Growth FactorsB Cell Growth Factor (BCGF)
  • 4. Gamma-InterferonInterleukin-1 (IL-1)Macrophage Activating Factor32. Immunohistochemical Stains33. Emerging Tumor MarkersN-AcetylglucosamineActinAlpha-ActinAntineuronal Antibodies7B2B72.3BaxBCD-F9BLCA-4Blood Group Antigens A,B,HCA 50CA 72-4/TAG-72CA 195CA-242CA-549CAM 26CAR-3Cathepsin-DChromogranin A and BCluster 1 AntigenCluster-5/5A AntigenCTACU18DR-70DU-PAN-2Endometrial Bleeding Associated FactorEndostatinEpithelial Membrane AntigenFeulgen HydrolysisFibronectinFSH(1->3)-L-fucosyltransferaseGastrin-Releasing Peptide (GRP)GDCFP-15GlucagonGlycoaminesH23
  • 5. Her-2Human Carcinoma AntigenHPAHSP27Intermediate FilamentsCytokeratins/CK18/Cyfra 21-1DesminGliofibrillary Acid ProteinNeurofilamentsVimentinKA 93KinasesKP16D3LAILeukocyte Common AntigenLewis AntigensLysophosphatidic Acid (LPA)Ma 695/Ma 552MABDF3MAGME1MinactivinMN/CA9MSAMucin Cancer Antigen (MCA)Multiple Tumor Suppressor 1MyosinNEA-130NMP22OA-519Opiod PeptidesP-glycoproteinPancreatic Oncofetal Antigen (POA)Placental LactogenPR92Proliferative Index, Ki-67PxRB Inactivation/DeletionRetSCCL 175SelectinSialic Acid
  • 6. Sialyl SSEA-1/SLXSN10SomatostatinTA-90TABATachykininTAG 12TPSTroponinTubulinVCAMVEGFVillenC. Instrumentation Review AndMarket Needs1. Abbott AxSYM2. Abbott Architect c40003. Abbott Architect i2000 Series4. Abbott Architect ci8200 SystemTable of Contents (continued)5. Beckman Coulter UniCel Series6. Beckman Coulter Access7. Binding Site ESP6008. bioMerieux Mini Vidas9. Carolina Chemistries BioLis 24i10. DiaSorin Liaison11. Horiba ABX Pentra 40012. Inverness DS213. J&J Vitros ECi/ECiQ14. J&J Vitros 360015. J&J Vitros 560016. Olympus AU540017. Olympus AU3000i18. Olympus AU270019. Roche Modular Analytics20. Roche Cobas Integra 40021. Roche Cobas Integra 400 Plus22. Roche Elecsys23. Roche Cobas c31124. Siemens ADVIA Centaur25. Siemens Dimension26. Siemens Dimension RxL Max
  • 7. 27. Siemens Dimension Vista 50028. Siemens Immulite29. Siemens Stratus30. Tosoh AIA-Series31. Vital Diagnostics ATAC 800032. Vital Diagnostics Envoy 500D. Current and Emerging Technologies1. Monoclonal and Polyclonal Antibodies2. Immunoassaysa. Technological Principleb. Radioimmunoassay (RIA)c. Enzyme Immunoassays (EIA)OverviewELISAImmunofiltrationParticle-Membrane Capture ImmunoassayEnzyme Amplificationd. Fluorescent Immunoassayse. LuminescenceChemiluminescenceBioluminescencef. Latex Agglutinationg. ImmunoprecipitationH. Affinity Chromatographue. Liposome Flow-Injection Immunoassay3. Molecular Diagnosticsa. Technology Overviewb. Amplification MethodsPCRDAP-PCRImmuno-PCRQC-PCRCARDNAHPALCRNASBAQBRSDA3 SR, and others4. Chromosome Analysisa. Chronic Myelogenous Leukemia (CML)
  • 8. b. Acute Myeloid Leukemia (AML)c. Acute Lymphoblastic Leukemia (ALL)d. Malignant LymphomasLymphoid Malignanciese. Chronic Lymphocytic Leukemia (CLL)f. Solid Cancersg. Chromosomal Translocation and Oncogenes5. Artificial Intelligence6. Flow Cytometry7. Two Dimensional Gel Electrophoresis (2-DGE)8. Biosensors9. Competing/Complementing Technologiesa. CTb. MRIc. NMRd. PETe. Photonics SpectroscopyE. Personal TestingU.S.A.A. Executive SummaryB. Business Environment1. Health Care Expenditures2. Cost Consciousness3. Industry Consolidation4. Managed Care5. Hospitals6. Admissions7. Length of Stay8. Industry Diversification9. Physician Demographics10. Population Aginga. Chronic Illnessb. Disease Incidencec. Susceptibility to Iatrogenesisd. Multiple Illness Cases11. Laboratory RegulationsC. Market Structure1. Centralized Testinga. Hospitalsb. Commercial/Private Laboratories2. POT/Decentralized Testinga. Physician Offices/Group Practices
  • 9. b. Cancer Clinicsc. Point-Of-Care Testingd. Other Decentralized Testing LocationsD. Market Size, Growth and Major Suppliers Sales,Instrument Placements and Market SharesMajor Product Development OpportunitiesA. Reagent Kits and Test Systems/PanelsB. InstrumentationC. Computers, Software and AutomationD. Auxiliary ProductsDesign Criteria for Decentralized Testing ProductsAlternative Market Penetration StrategiesA. Internal DevelopmentB. Collaborative ArrangementsC. University ContractsD. Distribution Strategies1. Marketing Approaches2. Product Complexity3. Customer Preference4. Established Suppliers5. Emerging Suppliers6. Major Types of Distributors7. Market Segmentation FactorPotential Market Entry Barriers and RisksA. Market MaturityB. Cost ContainmentC. CompetitionD. Technological Edge and LimitationsE. Patent ProtectionF. Regulatory ConstraintsG. Decentralized Testing Market ChallengesCompetitive ProfilesAbbottAdnaGenApplied Gene TechnologiesArcaBeckman Coulter/DanaherBecton DickinsonBiomedical DiagnosticsbioMerieuxBio-RadCepheid
  • 10. Correlogic SystemsDakoDecodeDiadexusDiagnocureDiasorinEiken ChemicalEnterixEnzo BiochemEpigenomicsExact SciencesFujirebioGen-ProbeGuided TherapeuticsHologicIpsogenKreatechKyowa MedexLife TechnologiesMackay Life SciencesMyriad GeneticsNanogen ElitechOncoLabOtho-Clinical DiagnosticsPanacea PharmaceuticalsPolartechnicsPolymedcoPreMDQiagenRadient PharmaceuticalsRocheScienionSequenomSiemens HealthcareTakara BioTargeted Diagnostics & TherapeuticsTosohVeridexWako Pure ChemicalsWallac/PEZila
  • 11. AppendixesAppendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technologyand ApplicationsAppendix II: Assumed Currency Exchange RatesList of TablesTumor Marker ClassificationMajor Companies Developing or Marketing ACTH TestsMajor Companies Developing or Marketing AFP TestsMajor Companies Developing or Marketing Beta-2 Microglobulin TestsMajor Companies Developing or Marketing CA 15-3/27.29 TestsMajor Companies Developing or Marketing CA 19-9 TestsMajor Companies Developing or Marketing CA 125 TestsMajor Companies Developing or Marketing Calcitonin TestsMajor Companies Developing or Marketing CEA TestsMajor Companies Developing or Marketing Estrogen Receptor TestsMajor Companies Developing or Marketing Progesterone Receptor TestsMajor Companies Developing or Marketing Ferritin TestsMajor Companies Developing or Marketing Gastrin TestsMajor Companies Developing or Marketing HCG TestsMajor Companies Developing or Marketing Insulin TestsMajor Companies Developing or Marketing NSE TestsMajor Companies Developing or Marketing Occult Blood TestsMajor Companies Developing or Marketing PAP Smear/HPV TestsMajor Companies Developing or Marketing PAP TestsMajor Companies Developing or Marketing PSA TestsMajor Companies Developing or Marketing Lymphocyte Subclassification TestsBiochemical Markers Potential Applications In Cancer DiagnosisOncogenes Potential Applications In Cancer DiagnosisMajor Companies Developing or Marketing Oncogene TestsGrowth Factors Potential Applications In Cancer DiagnosisColony Stimulating Factors Potential Applications in Cancer DiagnosisLymphokines Potential Applications In Cancer DiagnosisImmunohistochemical Stains Potential Applications in Cancer DiagnosisExecutive Summary Table: U.S., Total Tumor Marker Test Volume and Sales Forecast by MarketSegmentU.S., Estimated New Cancer Cases and DeathsU.S., Estimated Cancer Death Rates Per 100,000 PopulationU.S., Laboratories Performing Tumor Marker Tests by Market SegmentU.S., Hospital Laboratories Performing Tumor Marker Tests by Bed SizeU.S., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test VolumeU.S., Physician Office Laboratories Performing Tumor Marker Tests by Practice SizeU.S., Total Tumor Marker Test Volume Forecast by Market Segment-201
  • 12. U.S., All Market Segments Major Tumor Marker Test Volume ForecastU.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by TestU.S., Commercial/Private Laboratories Major Tumor Marker Test Volume ForecastU.S., Physician Offices/Group Practices Major Tumor Marker Test Volume ForecastU.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by TestU.S., Total Tumor Marker Sales Forecast by Market SegmentU.S., All Market Segment Major Tumor Marker Sales Forecast by TestU.S., Hospital Laboratories Major Tumor Marker Sales Forecast by TestU.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by TestU.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by TestU.S., Cancer Clinics Major Tumor Marker Sales Forecast by TestU.S., ACTH Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., AFP Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Beta-2 Microglobulin Test Volume And Diagnostics Sales Forecast by Market SegmentU.S., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., CA-125 Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Calcitonin Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., CEA Test Volume and Diagnostics Sales by Market SegmentU.S., Chromogranin Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Colon-specific Antigen Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., HCG Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Insulin Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Interferons Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Interleukins Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., NSE Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Occult Blood Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., PAP Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
  • 13. U.S., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by MarketSegmentU.S., TDT Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., TPA Test Volume and Diagnostics Sales Forecast by Market SegmentU.S., Total Tumor Marker Sales By Major SupplierU.S., ACTH Testing Market Diagnostics Sales by Major SupplierU.S., AFP Testing Market Diagnostics Sales by Major SupplierU.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major SupplierU.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major SupplierU.S., CA 19-9 Testing Market Diagnostics Sales by Major SupplierU.S., CA 125 Testing Market Diagnostics Sales by Major SupplierU.S., CEA Testing Market Diagnostics Sales by Major SupplierU.S., Ferritin Testing Market Diagnostics Sales by Major SupplierU.S., HCG Testing Market Diagnostics Sales by Major SupplierU.S., Insulin Testing Market Diagnostics Sales by Major SupplierU.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major SupplierU.S., PAP Testing Market Diagnostics Sales by Major SupplierU.S., Progesterone Receptor Testing Market Diagnostics Sales by Major SupplierU.S., PSA Testing Market Diagnostics Sales by Major SupplierContact: sales@reportsandreports.com for more information.

×